Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $92 | $59 | $58 | $72 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $54 | $53 | $46 | $40 |
| Inventory | $67 | $67 | $53 | $48 |
| Other Curr. Assets | $11 | $6 | $6 | $7 |
| Total Curr. Assets | $224 | $186 | $163 | $168 |
| Property Plant & Equip (Net) | $27 | $28 | $28 | $28 |
| Goodwill | $23 | $23 | $23 | $23 |
| Intangibles | $91 | $94 | $96 | $99 |
| Long-Term Investments | $0 | $0 | $4 | $4 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $5 | $5 | $1 | $1 |
| Total NC Assets | $146 | $149 | $152 | $155 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $370 | $335 | $315 | $323 |
| Liabilities | – | – | – | – |
| Payables | $7 | $9 | $6 | $2 |
| Short-Term Debt | $6 | $6 | $18 | $21 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $103 | $80 | $71 | $77 |
| Total Curr. Liab. | $116 | $95 | $95 | $100 |
| LT Debt | $32 | $251 | $251 | $250 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $223 | $8 | $5 | $2 |
| Total NC Liab. | $255 | $259 | $256 | $252 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $39 | $39 | $39 |
| Total Liabilities | $371 | $354 | $351 | $353 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$682 | -$683 | -$681 | -$672 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $682 | $664 | $646 | $642 |
| Total Equity | -$1 | -$19 | -$35 | -$30 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $370 | $335 | $315 | $323 |
| Net Debt | -$53 | $198 | $210 | $200 |